伊布鲁替尼的氧降解不稳定促进了扩散型大B细胞淋巴瘤 (DLBCL) 的铁亡
Anuschka Langpape1,2,3, Debora Bonasera3,4,5, Jenny Stroh1,2
1Department of Translational Genomics, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Cell death discovery
|November 1, 2025
概括
这项研究揭示了细胞死亡途径铁亡,作为扩散型大B细胞淋巴瘤 (DLBCL) 的有前途的添加疗法. 在DLBCL模型中,将ferroptosis诱导与ibrutinib相结合提高了治疗疗效.
科学领域:
- 在瘤学瘤学.
- 细胞死亡途径 细胞死亡途径
- 血液学恶性瘤是什么
背景情况:
- 扩散型大B细胞淋巴瘤 (DLBCL) 呈现出显著的临床异质性和耐治疗性,特别是在高风险亚型中.
- 目前的DLBCL疗法主要集中在细胞亡上,而非细胞亡的细胞死亡机制尚未得到充分研究.
- 了解替代细胞死亡途径对于开发新型治疗策略至关重要.
研究的目的:
- 在DLBCL中作为潜在的治疗点,研究铁灭菌.
- 评估ferroptosis诱导和ibrutinib在DLBCL治疗中的添加效应.
- 阐明易布鲁替尼增强铁灭症敏感性的机制.
主要方法:
- 对DLBCL细胞的转录和脂质分析.
- 抑制GPX4以诱导铁亡.
- 用GPX4抑制和ibrutinib进行组合治疗的研究.
- 调查ibrutinib在铁亡途径上的分子活动.
主要成果:
- DLBCL细胞表达了核心铁灭保护机制的高水平.
- 在DLBCL模型中,GPX4抑制触发了快速的脂质ROS积累和细胞死亡.
- 易布鲁丁尼显示了GPX4抑制的附加效应,增强了铁灭的敏感性.
- 易布鲁替尼作为一种谷氨清除剂,并抑制GPX4蛋白表达.
结论:
- 铁化作为DLBCL添加疗法的可行基础,特别是在与ibrutinib结合使用时.
- 易布鲁替尼在调节抗氧化剂防御方面具有未被识别的活性,从而增强铁亡.
- 这些发现为克服DLBCL治疗耐药性的新疗法提供了新的治疗途径.
相关概念视频
01:46Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:16Necrosis
6.3K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
6.3K
01:31The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
01:10Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K